Lazertinib(Leclaza)

Release date: 2026-01-05 14:22:22     Recommended: 34

It is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion